Company Encyclopedia
View More
name
CHENGYIPHARMA
603811.SH
Zhejiang Cheng Yi Pharmaceutical Co., Ltd. produces and sells APIs, injections, capsules, tablets, pharmaceutical intermediates in China. The company was formerly known as Wenzhou No. 3 Pharmaceutical Factory and changed its name to Zhejiang Cheng Yi Pharmaceutical Co., Ltd.
3.165 T
603811.SHMarket value -Rank by Market Cap -/-

Financial Score

08/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking67/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE17.64%A
    • Profit Margin28.62%A
    • Gross Margin77.85%A
  • Growth ScoreC
    • Revenue YoY7.94%B
    • Net Profit YoY36.34%B
    • Total Assets YoY-6.92%D
    • Net Assets YoY6.46%B
  • Cash ScoreC
    • Cash Flow Margin349.39%C
    • OCF YoY7.94%B
  • Operating ScoreC
    • Turnover0.45C
  • Debt ScoreA
    • Gearing Ratio21.44%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Zhejiang CHENGYIPHARMA's subsidiary completes the compensated recovery of land and associated assets

    Zhejiang CHENGYIPHARMA's subsidiary Jiangsu CHENGYIPHARMA signed an asset acquisition agreement with relevant parties in the Qingjiangpu District of Huai'an City, completing the compensated recovery of land and ancillary assets, with an acquisition cost of CNY 126.988 million. As of the announcement date, the company has received CNY 114.098 million and expects to increase its revenue by CNY 9.5 million this year, with no adverse impact on the company's normal operations

    Zhitong·
    SH
    603811
    -0.73%
    Zhitong·
    SH
    603811
    -0.73%

    CHENGYIPHARMA: CHENGYI Microfinance and Yan Xiaoling plan to reduce their holdings by a total of no more than 1.18% of the company's shares

    According to the announcement from Zhitong Finance APP, CHENGYIPHARMA announced that within three months after 15 trading days from the date of this announcement, Chengyi Microfinance and Yan Xiaoling plan to reduce their holdings of the company's unrestricted circulating shares obtained through centralized bidding by no more than 3.8756 million shares, accounting for 1.18% of the company's total share capital

    Zhitong·
    SH
    603811
    -0.73%
    Zhitong·
    SH
    603811
    -0.73%

    CHENGYIPHARMA: The hydrochloride injection of dobutamine has passed the consistency evaluation of generic drugs

    According to the Zhitong Finance APP, CHENGYIPHARMA announced that the company recently received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration. The hydrochloride of dobutamine injection produced by the company has passed the consistency evaluation of quality and efficacy for generic drugs. The hydrochloride of dobutamine injection is mainly used for heart failure caused by decreased myocardial contractility in organic heart disease, including low cardiac output syndrome caused by direct cardiac surgery, as a short-term supportive treatment

    Zhitong·
    SH
    603811
    -0.73%
    Zhitong·
    SH
    603811
    -0.73%

    CHENGYIPHARMA: Ethyl Eicosapentaenoate Soft Capsules have obtained the drug registration certificate

    CHENGYIPHARMA announced that its eicosapentaenoic acid ethyl ester soft capsules have obtained the drug registration certificate from the National Medical Products Administration. This drug is used to lower triglyceride levels in adult patients with severe hypertriglyceridemia based on dietary control and can be used in conjunction with statins to reduce the risk of cardiovascular events. The impact on the risk of pancreatitis in patients with severe hypertriglyceridemia has not yet been assessed

    Zhitong·
    SH
    603811
    -0.73%
    Zhitong·
    SH
    603811
    -0.73%

    CHENGYIPHARMA released its semi-annual performance, with a net profit attributable to the parent company of 112 million yuan, a year-on-year increase of 47.03%

    According to the Zhitong Finance APP, CHENGYIPHARMA disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 417 million yuan, a year-on-year increase of 17.11%; net profit attributable to the parent company was 112 million yuan, a year-on-year increase of 47.03%; net profit excluding non-recurring gains and losses was 111 million yuan, a year-on-year increase of 54.21%; basic earnings per share were 0.35 yuan

    Zhitong·
    SH
    603811
    -0.73%
    Zhitong·
    SH
    603811
    -0.73%
    © 2025 Longbridge｜Disclaimer